JaneWinterMD
Hematology • Chicago, ILHematologic Oncology
Professor in Medicine-Hematology/Oncology, Feinberg School of Medicine, Northwestern University
Dr. Winter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
675 N Saint Clair St, 21-100 Galter Pavilion
Chicago, IL 60611Phone+1 312-695-0990Fax+1 312-695-4770
Summary
- Dr. Jane Winter, MD is a Hematologist based in Chicago, IL, with a subspecialty in Hematologic Oncology. She has extensive experience in treating non-Hodgkin lymphoma and Hodgkin's lymphoma. Dr. Winter is trained in Hematology and Medical Oncology from McGaw Medical Center of Northwestern University and the New York Presbyterian Hospital. Her residency was undertaken in Internal Medicine at the University of Chicago and she is an alumnus of the Perelman School of Medicine at the University of Pennsylvania. Dr. Winter has contributed significantly to the field with numerous publications in Blood Advances, particularly on lymphomas and CAR-T therapy. She has extensive experience as a principal investigator for multiple clinical trials, working primarily with lymphoma treatments. Her consistent excellence in her field has earned her a host of honors including being recognized multiple times as one of "America's Top Doctors" by Castle Connolly.
Education & Training
McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 1981 - 1982
New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 1980 - 1981
University of ChicagoResidency, Internal Medicine, 1977 - 1980
Perelman School of Medicine at the University of PennsylvaniaClass of 1977
Certifications & Licensure
IL State Medical License 1978 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- Chicago Magazine: Top Doctors Castle Connolly, 2004, 2006, 2008, 2010, 2012, 2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma Start of enrollment: 2007 Jul 24
- Zevalin-beam for Aggressive Lymphoma Start of enrollment: 2007 Jun 01
- Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma Start of enrollment: 2011 Feb 09
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsSubsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy.Megan Melody, Narendranath Epperla, Geoffrey Shouse, Jason Romancik, Pamela Allen
Blood Advances. 2024-05-28 - 4 citationsImpact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy.Reem Karmali, Rushad Machhi, Narendranath Epperla, Geoffrey Shouse, Jason Romancik
Blood Advances. 2024-05-28 - A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen.Reem Karmali, Carlos Galvez, Mehdi Hamadani, Leo Gordon, Jane Winter
Blood Advances. 2024-04-09
Abstracts/Posters
- A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ LymphomasJane N. Winter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Brief Pembrolizumab(PEM) Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients with Classical Hodgkin Lymphoma (cHL): A Mul...Jane N. Winter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classi...Jane N. Winter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
Steep Price for Surviving Childhood Lymphoma: Epigenetic AgingDecember 13th, 2022- New Data: The Drug Ibrutinib May Help Some Younger Mantle Cell Lymphoma Patients Avoid a Stem Cell TransplantDecember 12th, 2022
- 'Unparalleled Times' in Hematology, but Workforce Issues PersistSeptember 26th, 2022
- Join now to see all
Professional Memberships
- President 2022
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
